cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.12996788
title: Copy-number variations in adult patients with chronic immune thrombocytopenia

description: Immune thrombocytopenia (ITP) is an autoimmune disease with heterogeneous background. FCGR2C mutations were defined in one third of the patients but genetic players have not been fully elucidated yet. Although childhood ITP present as benign, ITP in adulthood is chronic disease with treatment challenges. This study aimed to focus on adult ITP patients using a whole genome genotyping that is valuable approach to identify the responsible genomic regions for the disease. Herein 24 adult primary-refractory for ITP patients were evaluated using HumanCytoSNP12BeadChip,Illumina. Forty-six age and sex matched healthy individuals, and ptients awith nonhematological conditions were analyzed as controls. Identified CNV regions were verified by qRTPCR. T-cell receptor beta and delta (TCRB/TCRG) clonality were assessed by heteroduplex analysis in mosaic cases. Several CNV losses and gains were defined (losses:2q,7q,17q,19p, and gains: 1q,2p,3q,4q,7q,10q,12p,13q,14q,15q,17p,20q,21p,22q,Xp). Mosaic changes of different sizes (0.2-17.77Mb) were identified in five patients and three of them showed clonality. CNV regions that were unique to ITP patients were identified for the first time and among these genes, those related to immune regulation, and cellular trafficking were noteworthy. Conclusion: Identified CNV regions harbor several candidate genes, the functions of which might shed light on the pathogenesis of chronic ITP.
DOI: 10.6084/m9.figshare.12319724.v1
title: Infant vaccine co-administration: review of 18 years of experience with GSK’s hexavalent vaccine co-administered with routine childhood vaccines

description: The benefits of vaccine co-administration include improved vaccine acceptance and uptake resulting in an increased coverage and protection against multiple childhood diseases, with minimal medical visits. The diphtheria-tetanus-acellular pertussis-hepatitis B-poliomyelitis-<i>Haemophilus influenzae</i> type b vaccine (DTaP-HBV-IPV/Hib) has been available for more than 19 years and is recommended for co-administration with several other infant vaccines. This is a comprehensive review (34 studies, 21,000 participants) describing the immunogenicity and safety of DTaP-HBV-IPV/Hib when co-administered with 12 different vaccines in infants including pneumococcal, meningococcal, rotavirus or measles-mumps-rubella-varicella. Interactions among co-administered vaccines are complex. Therefore, co-administration data are critical before a vaccination regimen can be recommended. Co-administration of DTaP-HBV-IPV/Hib with other routinely administered vaccines was associated with high percentages of children achieving seroprotection/vaccine response against DTaP-HBV-IPV/Hib antigens. In addition, co-administration was not associated with clinically significant interference in immune responses to co-administered vaccines and was well tolerated. Increased systemic reactions observed with some combinations (DTaP-HBV-IPV/Hib + pneumococcal conjugate or meningococcal serogroup B vaccines) were mitigated by prophylactic paracetamol administration. The data reported here, which represent the most frequently used co-administrations of DTaP-HBV-IPV/Hib worldwide, support the concomitant administration of DTaP-HBV-IPV/Hib with other routinely recommended infant vaccines.
DOI: 10.6084/m9.figshare.12850415
title: Proteomic studies of common chronic pain conditions - a systematic review and associated network analyses

description: The lack of biomarkers indicating involved nociceptive and/or pain mechanisms makes diagnostic procedures problematic. Clinical pain research has begun to use proteomics. This systematic review covers proteomic studies of chronic pain cohorts and in relation to clinical variables. Searches in three databases identified 96 studies from PubMed, 161 from Scopus and 155 from Web of Science database. Finally, 27 relevant articles were included. Network analyses based on the identified proteins were performed. Small pain cohorts were investigated and the number of studies per diagnosis and tissue is small. The use of proteomics in chronic pain research is exploratory and larger proteomic studies are needed. It will be necessary to standardize the descriptions of the pain cohorts investigated. There is a need to identify the mechanisms underlying the whole clinical presentation of specific chronic pain conditions. Multivariate methods capable of handling and identifying intercorrelated protein patterns must be applied. Rather than focusing on a few proteins, future studies should use network analyses to investigate interactions and biological processes. Proteomics in combination with bioinformatics have a huge potential to identify previously unknown panels of proteins involved in chronic pain and relevant when devising new pain control strategies.
DOI: 10.6084/m9.figshare.12996788.v2
title: Copy-number variations in adult patients with chronic immune thrombocytopenia

description: Immune thrombocytopenia (ITP) is an autoimmune disease with heterogeneous background. FCGR2C mutations were defined in one third of the patients but genetic players have not been fully elucidated yet. Although childhood ITP present as benign, ITP in adulthood is chronic disease with treatment challenges. This study aimed to focus on adult ITP patients using a whole genome genotyping that is valuable approach to identify the responsible genomic regions for the disease. Herein 24 adult primary-refractory for ITP patients were evaluated using HumanCytoSNP12BeadChip,Illumina. Forty-six age and sex matched healthy individuals, and ptients awith nonhematological conditions were analyzed as controls. Identified CNV regions were verified by qRTPCR. T-cell receptor beta and delta (TCRB/TCRG) clonality were assessed by heteroduplex analysis in mosaic cases. Several CNV losses and gains were defined (losses:2q,7q,17q,19p, and gains: 1q,2p,3q,4q,7q,10q,12p,13q,14q,15q,17p,20q,21p,22q,Xp). Mosaic changes of different sizes (0.2-17.77Mb) were identified in five patients and three of them showed clonality. CNV regions that were unique to ITP patients were identified for the first time and among these genes, those related to immune regulation, and cellular trafficking were noteworthy. Conclusion: Identified CNV regions harbor several candidate genes, the functions of which might shed light on the pathogenesis of chronic ITP.
DOI: 10.6084/m9.figshare.12850415.v1
title: Proteomic studies of common chronic pain conditions - a systematic review and associated network analyses

description: The lack of biomarkers indicating involved nociceptive and/or pain mechanisms makes diagnostic procedures problematic. Clinical pain research has begun to use proteomics. This systematic review covers proteomic studies of chronic pain cohorts and in relation to clinical variables. Searches in three databases identified 96 studies from PubMed, 161 from Scopus and 155 from Web of Science database. Finally, 27 relevant articles were included. Network analyses based on the identified proteins were performed. Small pain cohorts were investigated and the number of studies per diagnosis and tissue is small. The use of proteomics in chronic pain research is exploratory and larger proteomic studies are needed. It will be necessary to standardize the descriptions of the pain cohorts investigated. There is a need to identify the mechanisms underlying the whole clinical presentation of specific chronic pain conditions. Multivariate methods capable of handling and identifying intercorrelated protein patterns must be applied. Rather than focusing on a few proteins, future studies should use network analyses to investigate interactions and biological processes. Proteomics in combination with bioinformatics have a huge potential to identify previously unknown panels of proteins involved in chronic pain and relevant when devising new pain control strategies.
DOI: 10.6084/m9.figshare.13077242.v1
title: <i>Haemophilus influenzae</i> type b disease in the era of conjugate vaccines: critical factors for successful eradication

description: Prior to implementation of <i>Haemophilus influenzae</i> type b (Hib)-conjugate vaccination programs in the 1990s, Hib was the commonest cause of bacterial meningitis in children aged &lt;5 years. While the burden of all Hib disease has significantly decreased in the post-vaccination era, Hib still accounted for &gt;29,000 deaths worldwide in children aged &lt;5 years in 2015. We reviewed literature data on the most widely used Hib vaccines and vaccination strategies which led to the global prevention and control of Hib disease and aim to highlight important factors for continued disease control and elimination in the future. More than 90% of countries worldwide have implemented Hib-conjugate vaccination in their national immunization programs. Vaccines containing Hib polyribosylribitol phosphate (PRP) conjugated with tetanus toxoid (Hib-TT) are the most commonly used. <i>Neisseria meningitidis</i> outer membrane protein complex of PRP (Hib-OMP) is also used. Although the kinetics of the immune response varies with Hib vaccine and schedule used, high control of Hib disease was observed in all settings/scenarios. Further improving global Hib vaccination coverage may result in disease elimination. <b>What is the context?</b> Haemophilus influenzae is causing a variety of diseases, from otitis media and sinusitis to invasive disease (e.g. meningitis and pneumonia). H. influenzae type b (Hib) was the most common cause of bacterial meningitis in children &lt;5 years of age, and especially among &lt;2-year-olds. Even with appropriate treatment, up to 40% of children with bacterial meningitis can suffer permanent disabilities and up to 5% will die. The development of vaccines to protect against Hib disease has started in the late 1970s and has culminated with the licensure of 4 Hib conjugate vaccines, of which 2 are currently widely used. <b>What is new?</b> In this review, we gathered evidence on the different Hib vaccines and vaccination strategies that have contributed to the global prevention and control of Hib disease. The review indicates: the incidence of Hib disease has decreased considerably due to the introduction of Hib vaccines in national immunization programs worldwide. However, Hib disease is not yet completely eradicated. the vaccines currently used offer protection against Hib over long periods of time. carriage of the pathogen by healthy individuals seem to be less frequent, but data are still needed to fully evaluate the impact of vaccination. other H. influenzae types are now more frequent. <b>Why is this important?</b> Despite the huge success of Hib vaccination, continuous surveillance is needed to anticipate potential re-emergences and devise the best strategies for prevention and control of disease. Hib vaccination should be considered in the few countries who have not yet implemented it, to decrease associated morbidity and mortality.
DOI: 10.6084/m9.figshare.13077242
title: <i>Haemophilus influenzae</i> type b disease in the era of conjugate vaccines: critical factors for successful eradication

description: Prior to implementation of <i>Haemophilus influenzae</i> type b (Hib)-conjugate vaccination programs in the 1990s, Hib was the commonest cause of bacterial meningitis in children aged &lt;5 years. While the burden of all Hib disease has significantly decreased in the post-vaccination era, Hib still accounted for &gt;29,000 deaths worldwide in children aged &lt;5 years in 2015. We reviewed literature data on the most widely used Hib vaccines and vaccination strategies which led to the global prevention and control of Hib disease and aim to highlight important factors for continued disease control and elimination in the future. More than 90% of countries worldwide have implemented Hib-conjugate vaccination in their national immunization programs. Vaccines containing Hib polyribosylribitol phosphate (PRP) conjugated with tetanus toxoid (Hib-TT) are the most commonly used. <i>Neisseria meningitidis</i> outer membrane protein complex of PRP (Hib-OMP) is also used. Although the kinetics of the immune response varies with Hib vaccine and schedule used, high control of Hib disease was observed in all settings/scenarios. Further improving global Hib vaccination coverage may result in disease elimination. <b>What is the context?</b> Haemophilus influenzae is causing a variety of diseases, from otitis media and sinusitis to invasive disease (e.g. meningitis and pneumonia). H. influenzae type b (Hib) was the most common cause of bacterial meningitis in children &lt;5 years of age, and especially among &lt;2-year-olds. Even with appropriate treatment, up to 40% of children with bacterial meningitis can suffer permanent disabilities and up to 5% will die. The development of vaccines to protect against Hib disease has started in the late 1970s and has culminated with the licensure of 4 Hib conjugate vaccines, of which 2 are currently widely used. <b>What is new?</b> In this review, we gathered evidence on the different Hib vaccines and vaccination strategies that have contributed to the global prevention and control of Hib disease. The review indicates: the incidence of Hib disease has decreased considerably due to the introduction of Hib vaccines in national immunization programs worldwide. However, Hib disease is not yet completely eradicated. the vaccines currently used offer protection against Hib over long periods of time. carriage of the pathogen by healthy individuals seem to be less frequent, but data are still needed to fully evaluate the impact of vaccination. other H. influenzae types are now more frequent. <b>Why is this important?</b> Despite the huge success of Hib vaccination, continuous surveillance is needed to anticipate potential re-emergences and devise the best strategies for prevention and control of disease. Hib vaccination should be considered in the few countries who have not yet implemented it, to decrease associated morbidity and mortality.
DOI: 10.5281/zenodo.4742440
title: Datasets of kranocytes

description: Datasets of kranocytes from different papers
DOI: 10.15468/4mndp4
title: Systematic redescription of Solen (Ensisolen) tehuelchus and Ensis macha (Bivalvia: Solenoidea) from Argentina, southwestern Atlantic Ocean

description: This dataset contains the digitized treatments in Plazi based on the original journal article Giacomino, Sebastián, Signorelli, Javier H. (2021): Systematic redescription of Solen (Ensisolen) tehuelchus and Ensis macha (Bivalvia: Solenoidea) from Argentina, southwestern Atlantic Ocean. Zootaxa 4964 (3): 541-558, DOI: https://doi.org/10.11646/zootaxa.4964.3.6
DOI: 10.25318/2310029201-eng
title: Trucking financial statistics, by carrier size

description: Trucking financial statistics, such as revenues and expenses, by carrier size.
DOI: 10.25318/2310029201-fra
title: Statistiques financières sur le camionnage, selon la taille des transporteurs

description: Statistiques financières sur le camionnage, tels que les revenus et les dépenses, selon la taille des transporteurs.
DOI: 10.25318/2310029301-eng
title: Trucking revenue distribution by type of movement, by province and territory

description: Trucking industry revenues broken down by domestic (within Canada) versus international (into or out of Canada), for each province or territory.
DOI: 10.15468/44rhf5
title: Two new species of the genus Bolboceras Kirby, 1819 (Coleoptera: Bolboceratidae Bolboceratinae) from India with an updated identification key of the Bolboceras nigricans Westwood, 1848 species group

description: This dataset contains the digitized treatments in Plazi based on the original journal article Kalawate, Aparna Sureshchandra, Hillert, Oliver (2021): Two new species of the genus Bolboceras Kirby, 1819 (Coleoptera: Bolboceratidae Bolboceratinae) from India with an updated identification key of the Bolboceras nigricans Westwood, 1848 species group. Zootaxa 4964 (3): 559-570, DOI: https://doi.org/10.11646/zootaxa.4964.3.7
DOI: 10.25318/2310029301-fra
title: Distribution des revenus tirés du camionnage selon le type de mouvement, selon les provinces et territoires

description: Revenus de l'industrie du camionnage ventilés selon les mouvements intérieurs (à l'intérieur des frontières nationales) versus internationaux (en provenance ou vers des pays étrangers), pour chaque province ou territoire.
DOI: 10.6084/m9.figshare.14479605.v1
title: Earth ArcMap Shapefiles

description: All ArcMap shapefiles relating to the terrestrial side of this study.
DOI: 10.6084/m9.figshare.7392509
title: Haptophyte diversity and vertical distribution explored by 18S and 28S ribosomal RNA gene metabarcoding and scanning electron microscopy. Supplementary files.

description: File 1. Haptophyte 28S rRNA gene sequence reference database including 184 sequences from cultures and their accession number.<br> p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 10.0px Helvetica} <br>File 2. Taxonomy of Haptophyte 28S rRNA gene sequence reference database.
DOI: 10.6084/m9.figshare.7392509.v1
title: Haptophyte diversity and vertical distribution explored by 18S and 28S ribosomal RNA gene metabarcoding and scanning electron microscopy. Supplementary files.

description: File 1. Haptophyte 28S rRNA gene sequence reference database including 184 sequences from cultures and their accession number.<br> p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 10.0px Helvetica} <br>File 2. Taxonomy of Haptophyte 28S rRNA gene sequence reference database.
DOI: 10.25318/2710036101-eng
title:  Introduction of different types of innovation, by industry and enterprise size

description: Percentage of enterprises that introduced product (good or service), by North American Industry Classification System (NAICS) code and enterprise size, based on a three-year observation period. Product innovation includes new or improved goods and new or improved services. Business process innovation is a new or improved process for one or more business activities or functions that differs significantly from this business’s previous business processes and that has been brought into use by this business in its internal or outward-facing operations.
DOI: 10.6084/m9.figshare.7392401
title: Seasonal dynamics of algal infecting viruses in the Skagerrak, North Atlantic and inferred interactions with protists. Supplementary files.

description: Table S1. Algal virus major capsid protein (MCP) OTUs at station OF2 at the outer Oslofjorden, Norway during March 2010 - June 2011, with number of reads in each sample and its taxonomic placement. OTUs marked in red were removed after subsampling.<br>File S1. Fasta file with virus MCP amino acid (AA) alignment used for complete phylogenetic tree in Figure S2.<br><br>File S2. Fasta file with virus MCP AA alignment used for phylogenetic tree with the 22 most abundant OTUs in Figure 1. <br>Figure S2. Phylogenetic tree (FastTree2) based on available Phycodnaviridae and Mimiviridae MCP reference sequences (black), virus OTUs found in a previous study in Raunefjorden, Norway (blue, Larsen et al. 2008) and all algal viruses OTUs obtained from Outer Oslofjorden, OF2 (red).<br><br>
DOI: 10.6084/m9.figshare.7392401.v1
title: Seasonal dynamics of algal infecting viruses in the Skagerrak, North Atlantic and inferred interactions with protists. Supplementary files.

description: Table S1. Algal virus major capsid protein (MCP) OTUs at station OF2 at the outer Oslofjorden, Norway during March 2010 - June 2011, with number of reads in each sample and its taxonomic placement. OTUs marked in red were removed after subsampling.<br>File S1. Fasta file with virus MCP amino acid (AA) alignment used for complete phylogenetic tree in Figure S2.<br><br>File S2. Fasta file with virus MCP AA alignment used for phylogenetic tree with the 22 most abundant OTUs in Figure 1. <br>Figure S2. Phylogenetic tree (FastTree2) based on available Phycodnaviridae and Mimiviridae MCP reference sequences (black), virus OTUs found in a previous study in Raunefjorden, Norway (blue, Larsen et al. 2008) and all algal viruses OTUs obtained from Outer Oslofjorden, OF2 (red).<br><br>
DOI: 10.25318/2710036101-fra
title: Introduction de différents types d'innovation, selon l'industrie et la taille de l’entreprise

description: Pourcentage d'entreprises ayant introduit des produits (biens ou services), selon le code du Système de classification des industries de l'Amérique du Nord (SCIAN) et la taille de l'entreprise, sur une période d'observation de trois ans. L'innovation de produits comprend les biens ou les services nouveaux ou améliorés. L’innovation de procédés d’entreprise est un processus nouveau ou amélioré pour une ou plusieurs activités ou fonctions de l’entreprise qui diffère de manière significative des processus de cette entreprise et qui a été mis en service par cette activité dans le cadre de ses activités internes ou externes.
DOI: 10.6084/m9.figshare.14547426
title: Annotated genome sequence of Rhodococcus qingshengii strain IGTS8

description: This genome has been annotated using RAST pipeline. The GenBank accession number for un-annotated genome is CP029297.1 - CP029321.1.
DOI: 10.15468/qk8z88
title: A further study on the wolf spider subfamily Artoriinae from China (Araneae: Lycosidae)

description: This dataset contains the digitized treatments in Plazi based on the original journal article Wang, Lu-Yu, Framenau, Volker W., Zhang, Zhi-Sheng (2021): A further study on the wolf spider subfamily Artoriinae from China (Araneae: Lycosidae). Zootaxa 4964 (3): 571-584, DOI: https://doi.org/10.11646/zootaxa.4964.3.8
DOI: 10.25318/3310027201-eng
title:  Process innovations that resulted in cost savings to support business functions, by industry and enterprise size

description: Percentage of enterprises that introduced process innovations that resulted in cost savings, to support business functions, by North American Industry Classification System (NAICS) code and enterprise size. Business process innovation is a new or improved process for one or more business activities or functions that differs significantly from this business’s previous business processes and that has been brought into use by this business in its internal or outward-facing operations.
DOI: 10.6084/m9.figshare.12901583
title: Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection

description: The novel SARS-CoV-2 coronavirus, the causative agent of the ongoing pandemic COVID-19 disease continues to infect people globally and has infected millions of humans worldwide. However, no effective vaccine against this virus exists. Using Immunoinformatics, epitopic sequences from multiple glycoproteins that play crucial role in pathogenesis were identified. Particularly, epitopes were mapped from conserved receptor-binding domain of spike protein which have been experimentally validated in SARS-CoV-1 as a promising target for vaccine development. A multi-epitopic vaccine construct comprising of B-cell, CTL, HTL epitopes was developed along with fusion of adjuvant and linkers. The epitopes identified herein are reported for the first time and were predicted to be highly antigenic, stable, nonallergen, nontoxic and displayed conservation across several SARS-CoV-2 isolates from different countries. Additionally, the epitopes associated with maximum HLA alleles and population coverage analysis shows the proposed epitopes would be a relevant representative of large proportion of the world population. A reliable three-dimensional structure of the vaccine construct was developed. Consequently, docking and molecular-dynamics simulation ensured the stable interaction between vaccine and innate-immune receptor.